Cardiac REhabilitation COhort at the Medicine Campus DaVos to invEstigate Recovery

NCT07096973 | Recruiting

• 1 other identifier: 2024-02560
• Study Type: observational
• Target: 10,000
• Locations: 1 country
• Sites: 1

Brief Summary

The RECOVER study, titled Cardiac Rehabilitation Cohort at the Medicine Campus Davos for Exploration of Recovery, is a prospective, non-interventional, monocentric cohort study conducted at the Hochgebirgsklinik Davos. The study is sponsored by Medicine Campus Davos AG and the Kühne Foundation, with an estimated start date in July 2025 and planned completion by December 2034, with the possibility of extension. The principal investigator of the study is PD Dr. David Niederseer from Hochgebirgsklinik Davos, who also represents the study. The research team includes co-investigators such as Prof. Dr. Stefan Blankenberg and Prof. Dr. Andreas Ziegler from Cardio-CARE, Medicine Campus Davos, as well as Dr. Jan Vontobel from Hochgebirgsklinik Davos. The study will enroll patients referred to Hochgebirgsklinik Davos for cardiac rehabilitation who provide informed consent. Cardiac rehabilitation is an evidence-based therapy for patients with heart disease, including those who have undergone cardiac procedures or surgeries. The primary objectives are to evaluate baseline patient characteristics, rehabilitation strategies, predictors of recovery, and clinical outcomes during and after rehabilitation. To support this, a detailed database and biobank will be established to allow for comprehensive phenotyping, extensive clinical assessments, and long-term follow-up. RECOVER seeks to gain translational insights into how patient-specific factors - such as genetics, plasma, digital and clinical biomarkers, and comorbidities - influence long-term clinical outcomes. The goal is to identify modifiable risk factors to optimize individualized therapeutic approaches in cardiac rehabilitation.

Conditions

Cardiac Rehabilitation; Heart Failure; Cardiac Arrest (CA); ACS (Acute Coronary Syndrome); CABG; Valve Anomalies; LVAD (Left Ventricular Assist Device); Heart Transplantation; Arrhythmia

Keywords

cardiovascular diseases; cardiac rehabilitation

Outcome Measures

Primary Outcomes (2)

• Composite of cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke, and hospitalization for heart failure

  Outcome assessment will be conducted through a combination of structured telephone follow-up, systematic collection of relevant medical records from the time of inclusion to the follow-up visit, patient-completed questionnaires, and analysis of data from national health and mortality registries.

  Follow-up 1, 5 and 10 years after inclusion

• Incidence of all-cause rehospitalization post cardiac intervention or surgery

  All-cause rehospitalization is defined as any unplanned hospital admission, regardless of cause, occurring following the index cardiac intervention or surgery. This includes admissions to any inpatient care facility for diagnostic, therapeutic, or emergency reasons, excluding planned elective procedures or routine follow-up admissions. Data will be obtained through structured follow-up, review of relevant hospital records, and linkage with national health insurance and hospital discharge registries to ensure comprehensive capture of rehospitalization events.

  Follow-up 1, 5 and 10 years after inclusion

Secondary Outcomes (5)

• Patient reported quality of life (QoL)

  Follow-up 1, 5 and 10 years after inclusion

• Re-surgery / Re-intervention

  Follow-up 1, 5 and 10 years after inclusion

• New-Onset Atrial Fibrillation

  Follow-up 1, 5 and 10 years after inclusion

• Cognitive Function

  Follow-up 1, 5 and 10 years after inclusion

• Functional Capacity

  Follow-up 1, 5 and 10 years after inclusion

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All patients referred to HGK for inpatient CR will be screened for eligibility according to inclusion and exclusion criteria. Study inclusion requires written informed consent, and the study and all -related procedures will be performed according to the Declaration of Helsinki. The study plans to enroll approximately 1'000 patients per year.

You may qualify if:

• Patients undergoing CR at the HGK
• Written informed consent
• Age ≥ 18 years

You may not qualify if:

• Insufficient knowledge of the German language to understand study documents, the interview, or questionnaires interview without translation
• Physical or psychological incapability to participate in the study

Sponsors & Collaborators

• Hochgebirgsklinik Davos: lead

Study Sites (1)

Hochgebirgsklinik Davos

Davos, Kanton Graubünden, 7265, Switzerland

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

* Blood (EDTA-blood, serum, plasma (EDTA), citrated), DNA, RNA, washed erythrocytes, PBMCs (peripheral blood mononuclear cell) * Urine * Stool * Tissue/ cells * Saliva * Hair

MeSH Terms

Conditions

Heart Failure; Heart Arrest; Acute Coronary Syndrome; Arrhythmias, Cardiac; Cardiovascular Diseases

Condition Hierarchy (Ancestors)

Heart Diseases; Myocardial Ischemia; Vascular Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Researchteam Hochgebirgsklinik Davos

CONTACT

+41 81 417 40 60; research@hgk.ch

Reception / Front Desk Hochgebirgsklinik Davos

CONTACT

+41 81 417 44 44; info@hgk.ch

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 10 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 21, 2025
• First Posted: July 31, 2025
• Study Start: August 5, 2025
• Primary Completion (Estimated): August 5, 2035
• Study Completion (Estimated): August 5, 2040
• Last Updated: September 17, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

CH (1)